A Phase 2a Multi-Center Study of 18F-FDG PET Safety and Tolerability of AZD0530 in Mild Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this research study is to determine whether AZD0530 is safe and effective in slowing decline in brain metabolism, memory and daily function in people with Alzheimer?s disease (AD).
Description
The purpose of this study is to test whether an oral experimental drug, AZD0530, will slow progression in mild-stage Alzheimer's disease.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 55 Years - 85 Years
-
Gender: All
Updated on
18 Apr 2024.
Study ID: 1501331796
